Additionally, ARID1A loss may also interfere with the immune checkpoint, promoting MLH1 silencing and upregulation of PD-L1 (programmed death ligand 1), leading to cancer cells escaping from immune checkpoint surveillance [37]. Here, MLH1 is linked to cancer.